Reviews/SGLT2 Inhibitors/SGLT2 inhibitors reduce CV death and HF hospitalisation in HFrEF
· SG-HF-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
In patients whose hearts pump weakly, one large, well-run trial of dapagliflozin [4] found that the drug lowered the combined risk of worsening heart failure and death from heart causes, and that each of those two outcomes moved in the right direction on its own. A second drug of the same class, empagliflozin, was represented in the corpus [18], but that report studied anaemia rather than giving its own headline result for the main outcome. Several other reports that look supportive [9], [15], [16] are further slices of the same dapagliflozin trial rather than new trials, and one real-world study [2] pointed the same way but was small, from a single centre, and in a different patient group. The panel judged the hospitalisation half of the claim to be the firmest part and the death half to be supported but less decisive. It landed where it did because the strongest evidence is one pivotal trial carrying the full numbers, with only partial back-up from a second drug.
DAPA-HF [4] enrolled 4744 patients with an ejection fraction of 40% or less and reduced the composite of worsening heart failure or cardiovascular death (hazard ratio 0.74), with worsening heart failure at 0.70 and cardiovascular death at 0.82. The composite effect held across background therapy in a subgroup analysis of the same cohort [9], and further analyses of that cohort on arrhythmia and sudden death [15] and anaemia [16] were directionally consistent. For empagliflozin, [18] reports in an HFrEF population (EMPEROR-Reduced) that the effect on the cardiovascular-death-or-hospitalisation composite was not modified by anaemia, but its abstract carries no headline hazard ratio for that composite. An observational single-centre study [2] of 222 patients with ischaemic heart failure reported a composite reduction (HR 0.24). The contested point: The evidence divides on the cardiovascular-death half of the claim: in the only in-corpus trial carrying full numbers [4], that hazard ratio is 0.82 with an upper bound reaching 0.98, and the composite is driven mainly by heart-failure events. The apparent breadth of support also narrows once it is seen that [9], [15] and [16] are all analyses of the single DAPA-HF cohort rather than independent trials.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The CV-death half of the claim rests on a single full-numbers trial ([4] DAPA-HF), where CV death HR 0.82 has a CI reaching 0.98 — significant but fragile; the composite is driven mainly by HF events, so 'reduce CV death' is weaker than 'reduce HFH'.
Apparent consistency is inflated by non-independence: [9], [15], [16] are all post hoc analyses of the same DAPA-HF cohort, not separate trials.
Where it remains uncertain. The cardiovascular-death component rests on a single full-numbers trial [4] with a confidence interval reaching 0.98, and the second agent appears only as an anaemia substudy [18] with no primary hazard ratio in its abstract.
Aleatory
In [4] the cardiovascular-death hazard ratio is 0.82 with a confidence interval reaching 0.98, leaving the effect significant but close to no effect by chance variation.
Epistemic
EMPEROR-Reduced enters the corpus only through an anaemia substudy [18]; the empagliflozin HFrEF primary composite hazard ratio is not in any abstract here.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Same-direction observational signal; weak/confounded, supportive only.
“statistically significant differences have been observed between the two groups in terms of the composite CV death/HFH (HR = 0.24; 95%CI [0.101-0.564]; p = 0.001)”
Panel auditInternal validity: low · scope of inference: Early versus late in-hospital SGLT2i initiation in ischaemic-aetiology HF at 6 months.Key limitations: observational single centre · population not defined by reduced EF · contrast is timing not drug vs control
Pivotal HFrEF RCT: composite of worsening HF or CV death significantly reduced.
“Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98)”
Panel auditInternal validity: high · scope of inference: Dapagliflozin versus placebo in NYHA II-IV heart failure with reduced ejection fraction (EF ≤ 40%).Key limitations: composite primary endpoint uses worsening HF (hospitalisation or urgent visit), not HFH alone
Composite benefit consistent across all background-therapy subgroups in HFrEF.
“the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65-0.85] for the primary composite endpoint (P < 0.0001)”
Panel auditInternal validity: high · scope of inference: Consistency of dapagliflozin benefit in HFrEF across background HF therapy.Key limitations: post hoc subgroup analysis · composite uses worsening HF event, not HFH alone
The primary composite outcome was reduced with dapagliflozin in both anaemic (HR 0.68) and non-anaemic (HR 0.76) patients, with CIs excluding 1, and similar findings for CV death and HF hospitalisation.
Panel auditInternal validity: high · scope of inference: Dapagliflozin benefit in HFrEF across baseline anaemia status.Key limitations: subgroup analysis · CV-death and HFH stated as consistent without separate estimates in abstract
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One pivotal HFrEF RCT with significant effects on both components plus partial second-trial corroboration carries an Established verdict, held at the band floor because full headline numbers come from a single trial and the mortality component is modest.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Missing primary hazard ratio for empagliflozin in HFrEF. The claim's class-level reading leans on a second agent, but the corpus gives only an anaemia substudy [18] with no headline composite effect for EMPEROR-Reduced. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Add the EMPEROR-Reduced primary-outcome report so the cardiovascular-death-or-hospitalisation hazard ratio for empagliflozin is in-corpus and independent of DAPA-HF.
Open question: Does empagliflozin reduce the cardiovascular-death-or-hospitalisation composite in HFrEF with a hazard ratio comparable to dapagliflozin? Why it is still open: The only empagliflozin HFrEF report in the corpus [18] is an anaemia substudy whose abstract carries no primary composite hazard ratio.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19